Literature DB >> 15687918

[Implantation of preserved human amniotic membrane for the treatment of shield ulcers and persistent corneal epithelial defects in chronic allergic keratoconjunctivitis].

N Rouher1, F Pilon, H Dalens, J-L Fauquert, J-L Kemeny, D Rigal, F Chiambaretta.   

Abstract

PURPOSE: To determine whether amniotic membrane implantation is a safe and effective alternative treatment for shield ulcers and persistent corneal epithelial defects associated with ulcers in chronic allergic keratoconjunctivitis (vernal or atopic keratoconjunctivitis).
METHODS: Amniotic membrane implantation was performed in four consecutive patients with persistent corneal epithelial defects or vernal plaques unresponsive to conventional medical treatment lasting an average of 18 weeks. Surgery was done under general anesthesia using amniotic membrane as a therapeutic contact lens.
RESULTS: A significant decrease in symptoms and complete reepithelialization of the corneal ulcers were observed in all cases within the first 7 days. These remained stable during a mean follow-up of 12 weeks, with no intraoperative or postoperative complications. Early detachment occurred in all cases with no negative consequences on ulcer healing.
CONCLUSION: Patients with severe chronic allergic keratoconjunctivitis derive benefits from amniotic membrane implantation used as a therapeutic contact lens in the treatment of persistent corneal epithelial defects and vernal plaques unresponsive to conventional medical treatment.

Entities:  

Mesh:

Year:  2004        PMID: 15687918     DOI: 10.1016/s0181-5512(04)96277-8

Source DB:  PubMed          Journal:  J Fr Ophtalmol        ISSN: 0181-5512            Impact factor:   0.818


  2 in total

1.  Supratarsal injection of triamcinolone acetonide and childhood allergic keratoconjunctivitis.

Authors:  Sonia Zaouali; Rim Kahloun; Sonia Attia; Bechir Jelliti; Manel Trigui; Salim Ben Yahia; Riadh Messaoud; Moncef Khairallah
Journal:  Int Ophthalmol       Date:  2012-02-14       Impact factor: 2.031

Review 2.  [Therapeutic options in vernal keratoconjunctivitis].

Authors:  E M Messmer
Journal:  Ophthalmologe       Date:  2009-06       Impact factor: 1.059

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.